COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

(2021) Jing-Hui Tian et al.   Nature Communications

A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice

(2021) Abigail E. Powell et al.   ACS Central Science

No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants

(2021) Qianqian Li et al.   CELL

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

(2021) Joshua G. Liang et al.   Nature Communications

A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach

(2021) Patricio Oyarzun et al.   Frontiers in Immunology

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Vaccines: Status Report

(2020) Fatima Amanat et al.   IMMUNITY

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Developing Covid-19 Vaccines at Pandemic Speed

(2020) Nicole Lurie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

(2020) Lianpan Dai et al.   CELL

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

(2020) Jiandong Huo et al.   Cell Host & Microbe

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

(2020) Xiaoli Wang et al.   CLINICAL INFECTIOUS DISEASES

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

(2020) Jingyun Yang et al.   NATURE

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

(2020) Daming Zhou et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct conformational states of SARS-CoV-2 spike protein

(2020) Yongfei Cai et al.   SCIENCE

COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning

(2020) Edison Ong et al.   Frontiers in Immunology

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

COVID-19 vaccine trials should seek worthwhile efficacy

(2020) Philip Krause et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Learning from the past: development of safe and effective COVID-19 vaccines

(2020) Shan Su et al.   NATURE REVIEWS MICROBIOLOGY

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

(2020) Angkana T. Huang et al.   Nature Communications

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

(2020) Omna Sharma et al.   Frontiers in Immunology

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

(2020) Rinke Bos et al.   npj Vaccines

Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection

(2020) Sang Heui Seo et al.   Vaccines

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Correlates of protection against SARS-CoV-2 in rhesus macaques

(2020) Katherine McMahan et al.   NATURE

The lightning-fast quest for COVID vaccines — and what it means for other diseases

(2020) Philip Ball   NATURE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintaining Safety with SARS-CoV-2 Vaccines

(2020) Mariana C. Castells et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

(2020) Susanne H Hodgson et al.   LANCET INFECTIOUS DISEASES

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

(2019) Zhiqi Song et al.   Viruses-Basel

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

(2019) Giulietta Maruggi et al.   MOLECULAR THERAPY

Novel prime-boost vaccine strategies against HIV-1

(2019) Jean-Louis Excler et al.   Expert Review of Vaccines

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

(2017) Kapil Bahl et al.   MOLECULAR THERAPY

Adenoviral vector-based strategies against infectious disease and cancer

(2016) Chao Zhang et al.   Human Vaccines & Immunotherapeutics

Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection

(2015) Jerome H. Kim et al.   Annual Review of Medicine

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

(2015) Feng-Cai Zhu et al.   LANCET

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

(2011) T. W. Geisbert et al.   JOURNAL OF VIROLOGY